PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jbcThe Journal of Biological Chemistry
 
J Biol Chem. 2010 August 20; 285(34): 26545–26557.
Published online 2010 June 17. doi:  10.1074/jbc.M110.143917
PMCID: PMC2924092

NADPH Oxidases Regulate CD44 and Hyaluronic Acid Expression in Thrombin-treated Vascular Smooth Muscle Cells and in Atherosclerosis*

Abstract

The intracellular signaling events by which NADPH oxidase-generated reactive oxygen species (ROS) modulate vascular smooth muscle cell (VSMC) function and atherogenesis are yet to be entirely elucidated. We previously demonstrated that NADPH oxidase deficiency decreased atherosclerosis in apoE−/− mice and identified adhesion protein CD44 as an important ROS-sensitive gene expressed in VSMC and atherosclerotic lesions. Here, we examined the molecular mechanisms by which NADPH oxidase-generated ROS regulate the expression of CD44 and its principal ligand, hyaluronan (HA), and how CD44-HA interaction affects VSMC proliferation and migration and inflammatory gene expression in apoE−/− mice aortas. Thrombin-induced CD44 expression is mediated by transcription factor AP-1 in a NADPH oxidase-dependent manner. NADPH oxidase-mediated ROS generation enhanced thrombin-induced HA synthesis, and hyaluronan synthase 2 expression in VSMC. Hyaluronidase, which generates low molecular weight HA (LMW-HA), is induced in VSMC in a NADPH oxidase-dependent manner and LMW-HA stimulated ROS generation and cell proliferation in wild-type but not p47phox−/− VSMC, effects that were enhanced by thrombin pretreatment. Haptotactic VSMC migration toward HA was increased by thrombin in a CD44-dependent manner. HA expression in atherosclerotic lesions and plasma-soluble CD44 and HA levels were higher in apoE−/− compared with apoE−/−/p47phox−/− mice. HA-regulated pro-inflammatory gene expression was higher in apoE−/− than apoE−/−/p47phox−/− mouse aortas. GKT136901, a specific inhibitor of Nox1- and Nox4-containing NADPH oxidase activity, attenuated ROS generation and atherosclerosis and decreased CD44 and HA expression in atherosclerotic lesions. Together, these data suggest that increased CD44 and HA expression and CD44-HA-dependent gene regulation may play a role in atherosclerosis stimulated by NADPH oxidase activation.

Keywords: AP-1 Transcription Factor, Cell Migration, Gene Knockout, Inflammation, Reactive Oxygen Species (ROS), Signal Transduction

Introduction

Atherosclerosis is a chronic inflammatory disease of the vessel wall in which reactive oxygen species (ROS)3-mediated activation of redox-sensitive transcription pathways modulates atherosclerotic plaque progression. Increased adhesion molecule expression and remodeling of extracellular matrix are among the major changes caused by the activation of redox-sensitive signaling pathways. NADPH oxidases are critical determinants of the redox status of the vessel wall and play a critical role in the pathophysiology of atherosclerosis.

Several homologs of the gp91phox (Nox2) catalytic moiety of multisubunit NADPH oxidase (Nox): Nox1, Nox3, Nox4, Nox5, Duox1 and Duox2, have been recently identified (1). All Nox homologs are transmembrane proteins that possess six transmembrane domains with conserved binding sites for FAD and NADPH and four heme-binding histidines in the third and fifth transmembrane domains. The Nox moieties have distinct subcellular localizations (2) and are differentially regulated. For the Nox2-containing NADPH oxidase, catalytic activity is initiated following assembly of cytosolic subunits p47phox and p67phox with the membrane-bound Nox2, a process that requires phosphorylation of p47phox and p67phox, protein-protein interaction, and binding of G protein Rac (1). In the case of Nox1 and Nox3-based NADPH oxidases, the cytosolic subunits p47phox and p67phox are replaced by Nox organizer 1 and Nox activator 1, respectively. The activation of Nox4 does not require any of the cytosolic subunits mentioned above. However, Lyle et al. (3) recently reported that polymerase Δ-interacting protein 2 associates with p22phox to activate Nox4-based NADPH oxidase. Nox1- and Nox4-based enzymes are the predominant NADPH oxidases in mouse vascular smooth muscle cells (VSMC).

CD44 is a major cell surface adhesion molecule expressed on many vascular cell types including leukocytes, macrophages, endothelial cells, and VSMC. The expression of CD44 is regulated in a NADPH oxidase-dependent manner (4). In its extracellular domain, CD44 contains hyaluronan-binding site through which it anchors hyaluronic acid (HA) to the cell surface. The binding of HA to CD44 has been shown to regulate cell activation, proliferation, migration, signal transduction, and gene expression (5).

Consistent with its pleiotropic function, altered expression or dysfunction of CD44 has been proposed to be contributory in several pathological conditions. CD44 expression is up-regulated in mouse and human atherosclerotic lesions (4, 6,8) and in neointimal VSMC after arterial injury (4, 9). CD44-deficient apoE−/− mice develop markedly decreased atherosclerosis as compared with wild-type apoE−/− littermates (6). Proteolytic cleavage of the CD44 extracellular domain from the cell surface by metalloproteases generates soluble CD44, and circulating soluble CD44 levels are increased in humans with various inflammatory diseases and malignancies (10, 11). To date, a direct association between circulating soluble CD44 levels and human atherosclerosis has not been clearly established (12).

HA, a major glycosaminoglycan constituent of the extracellular matrix, is the principal ligand of CD44. HA also binds to other cell surface receptors such as RHAMM (receptor for HA-mediated motility) and LYVE-1 (lymphatic vessel endothelial HA receptor). HA polymers range in sizes and have wide ranging and sometimes opposing biological function depending on the size (13). Interaction of HA with cell surface receptors and a variety of hyaladherins such as link protein, versican, and tumor necrosis factor-induced gene-6 can result in the formation of extracellular matrix that makes up the microenvironment of VSMC (14).

HA is synthesized on the cytoplasmic surface of the plasma membrane by integral glycosyl transferases and is exported directly into the extracellular space (15). There are three distinct HA synthase genes (Has1, Has2, and Has3) in mammals. HAS2 is the major HAS isoform in VSMC (16). Constant HA turnover occurs under normal physiologic conditions and the increase in HA levels during pathophysiologic conditions reflects the balance between its synthesis and catabolism. Hyaluronidase is the enzyme that degrades HA and two distinct hyaluronidase genes (Hyal1 and Hyal2) have been reported to be involved in the intracellular and extracellular catabolism of HA in a CD44-dependent manner (17). In addition, ROS can degrade HA under oxidative conditions (18).

Because of its interaction with cell surface receptors, HA affects cell behavior through direct receptor-mediated effects on gene expression (19). Alterations in HA metabolism, distribution, and function have been documented in many diseases (14). HA was shown to regulate VSMC proliferation and activation in vitro (6) and overexpression of HA in aortic VSMC of apoE−/− mice has been shown to promote atherosclerosis development (20). Increased HA levels have been observed in injured rat carotid arteries and human restenotic arteries and atherosclerotic lesions (21, 22). Increased HA synthesis by saphenous vein VSMC is thought to contribute to saphenous vein graft failure in bypass patients (23) and selective accumulation of HA is associated with the proliferation and migration of VSMC and thrombosis of eroded plaques (22).

In the present study, we investigated the role of NADPH oxidases in thrombin-induced regulation of CD44 and HA expression in mouse VSMC and atherosclerosis. Our results demonstrate that NADPH oxidase plays a critical role in the regulation of both CD44 and HA expression in VSMC treated with thrombin. Low molecular weight HA (LMW-HA) enhances thrombin-induced NADPH oxidase activity and proliferation of VSMC, and HA-induced VSMC proliferation is regulated in a CD44-dependent manner. Absence of NADPH oxidase results in decreased levels of HA in the atherosclerotic lesions and soluble CD44 in the plasma and inflammatory gene expression in the aortic wall of apoE−/− mice. Additionally, our data suggest that Nox1- and Nox4-based NADPH oxidase inhibitors attenuate CD44 and HA expression in human aortic SMC and apoE−/− mice and decrease oxidative stress and atherosclerosis in the aortas of apoE−/− mice.

EXPERIMENTAL PROCEDURES

Chemicals and Reagents

If not stated otherwise, all chemicals were obtained from Sigma. 2,3-Dimethoxy-1,4-naphthoquinone (DMNQ) was purchased from Calbiochem. LMW-HA fragments were generated by sonication (24). Human α-thrombin was purchased from Hematologic Technologies, Inc. Rabbit anti-CD44 antibody and goat anti-HAS2 antibody were purchased from Santa Cruz Biotechnology. Mouse anti-β-actin antibody was obtained from Sigma. [3H]Thymidine and UDP-[14C]glucuronic acid were from PerkinElmer Life Sciences. GKT136901 (2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-yl-methyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione), a small molecule dual Nox1/Nox4 inhibitor (25) was provided by GenKyoTex S.A, and prepared in 0.5% carboxymethylcellulose, 0.25% Tween 20, 1% dimethyl sulfoxide. Luciferase reporter construct containing the human CD44 promoter fragment with regular or mutated AP-1 binding site were generously provided by Dr. Ashok Kumar, University of Ottawa (26).

Cell Culture

VSMC were isolated from aortas of 4-month-old wild-type, p47phox−/− and CD44−/− C57BL/6 mice as previously described (27). Aortas were dissected and digested with collagenase to remove adventitia and endothelium and then digested with collagenase and elastase at 37 °C for 1 h. VSMC were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS) as previously described (28). Human aortic smooth muscle cells (HASMC) were purchased from Invitrogen and grown in smooth muscle basal medium supplemented with growth factors (SmGM-2, Lonza). All experiments were conducted using VSMC between passages 4 and 11 that were growth arrested by incubation in DMEM containing 0.1% FBS for 72 h.

Mice and Diet

Wild-type, p47phox−/−, CD44−/−, apoE−/−, and apoE−/−/p47phox−/− mice were bred in-house as previously described (29). All mice were on C57BL/6 genetic background. p47phox−/− and CD44−/− mice were backcrossed for 10 generations. Animals were maintained at 22 °C with a 12-h light/dark cycle and were fed standard rodent chow until 7–8 weeks of age and then a Western diet (42% fat, Harlan Teklad/TD88137) for 12 more weeks. GKT136901, at a concentration of 10 mg/kg of body weight, was delivered through oral gavage using 20-gauge gavage needles once daily and 5 days a week for 12 weeks. All procedures involving the experimental animals were performed in compliance with protocols approved by University of North Carolina IACUC according to NIH guidelines.

AP-1 Transcription Factor Activity

Nuclear extracts from thrombin- and vehicle-treated VSMC were prepared with the NucBuster Protein Extraction Kit (Novagen) according to the manufacturer's protocol. AP-1 DNA binding activity was measured using the TransBinding AP-1 Assay Kit (Panomics). Briefly, nuclear extracts were incubated with biotinylated AP-1-consensus binding sequence oligonucleotides and the complexes bound to the oligonucleotides were detected using a primary AP-1 antibody and a secondary antibody conjugated to horseradish peroxidase. AP-1 activity was assayed by measuring the absorbance at 450 nm.

Nuclear Run-on Assay

Nuclei from thrombin-, DMNQ-, and vehicle-treated VSMC were isolated by lysing cells in 250 μl of lysis buffer (10 mm NaCl, 3 mm MgCl2, 10 mm Tris-HCl, 0.5% Nonidet P-40, pH 7.4) and then resuspended in nuclei storage buffer (40% glycerol, 50 mm Tris-HCl, 5 mm MgCl2, 0.1 mm EDTA, pH 8.5). Run-on transcription was done at room temperature for 30 min in a 100-μl volume with 2× reaction mixture containing 4× reaction buffer (100 mm HEPES, 10 mm MgCl2, 10 mm DTT, 300 mm KCl, 20% glycerol), 1 mm NTPs, and 250 μCi of [α-32P]UTP. Reactions were stopped by the addition of 2 units of DNase I at 37 °C for 10 min followed by incubation with 300 μl of stop buffer (2% SDS, 7 m urea, 0.35 m NaCl, 1 mm EDTA, 10 mm Tris-HCl, pH 8.0) and 15 μl of proteinase K (Qiagen) at 45 °C for 2 h. Dot blots containing 10 μg of denaturated CD44 and 18 S cDNAs were hybridized with nuclear run-on products in 5 ml of QuikHyb Hybridization Solution (Stratagene) at 42 °C for 24 h. The membranes were washed twice for 15 min at room temperature with 2× SSC, 0.1% SDS and then once for 30 min at 60 °C with 0.1× SSC, 0.1% SDS. Blots were analyzed by autoradiography.

RNA Extraction and Real Time RT-PCR

Total RNA from untreated and thrombin-treated wild-type and p47phox−/− cells was extracted using the RNeasy Micro Kit (Qiagen). RNA from mouse aortas was extracted with the MELTTM Total Nucleic Acid Isolation System (Ambion). Reverse transcription was performed with 1 μg of total RNA using a TaqMan Reverse Transcription Reagent kit (Applied Biosystems). TaqMan Gene Expression Assays for mouse Cd44 (Mm01277161_m1), Has2 (Mm00515089_m1), Hyal3 (Mm00662097_m1), Ccl2 (Mm00441242_m1), Ccl4 (Mm00443111_m1), Ccl5 (Mm01302428_m1), Tnfα (Mm00443258_m1), Il1β (Mm00434228_m1), Igf1 (Mm00439560_m1) and for human Cd44 (Hs01075861_m1), Has2 (Hs00193435_m1), Nox1 (Hs00246589_m1), and Nox4 (Hs00418356_m1) were purchased from Applied Biosystems. Real time RT-PCR was carried out using the ABI PRISM 7900 HT Sequence Detection System and TaqMan PCR Master Mix according to the manufacturer's recommendations. Sequence Detection System software (Applied Biosystems) was used for raw data processing and analysis. The data for each gene were analyzed by REST2005 (Relative Expression Software Tool) (30). Relative expression of each gene was determined by normalization to 18 S ribosomal RNA expression.

Transient Transfection and Luciferase Activity Assay

VSMC were transfected with CD44 promoter luciferase reporter or pCMV-β-galactosidase constructs using the GenJet In Vitro DNA Transfection Kit for SMC (SignaGen Laboratories) as recommended by manufacturer. Cell suspensions were incubated for 20 min at 37 °C with 1 μg of CD44 promoter constructs and 0.5 μg of pCMV-β-galactosidase constructs mixed with 6 μl of GenJet reagent and serum-free DMEM. Fresh 10% FBS/DMEM was added to the mixture and cells were plated on 12-well plates. After 24 h, cells were quiesced in 0.1% FBS/DMEM for 72 h. Cells were treated with thrombin or vehicle for 8 h and lysed in GloLysis buffer (Promega). Cell lysate was mixed with either Bright-Glo luciferase substrate or Beta-Glo galactosidase substrate (Promega) in equal amounts. After a 10-min incubation, luminescence was measured using Wallac 1420 Multilabel plate reader.

Measurement of CD44 mRNA Stability

VSMC were treated with thrombin or vehicle for 4 h prior to the addition of actinomycin D (5 μg/ml). RNA was extracted at 0, 2, 4, and 6 h and analyzed with real time RT-PCR as described above.

Rac1 Activation Assay

Cell lysates from thrombin- and LMW-HA-treated VSMC were analyzed for Rac1 activation using the PAK-1 PBD pull-down method (Rac1 Activation Assay Kit, Millipore). This assay uses the Rac downstream effector, p21-activated protein kinase (PAK), to isolate the active GTP-bound form of Rac from the sample. The p21 binding domain (PBD) of PAK-1 is expressed as a GST fusion protein and coupled to agarose beads. Cell lysates were precleared with 100 μl of glutathione-agarose and then immunoprecipitated with 10 μg of PAK-1 PBD at 4 °C overnight. Agarose beads were washed and analyzed by Western blot using mouse anti-Rac1 antibody. Nonimmunoprecipitated lysates were analyzed by Western blot to adjust for protein loading.

Western Analysis

Western analysis was performed as described previously (28).

Intracellular ROS Detection

VSMC grown in glass-bottom plates were washed with Hanks' buffered salt solution and loaded with 10 μm H2DCFDA (Invitrogen) in Hanks' buffered salt solution at 37 °C for 30 min and stimulated with Hanks' buffered salt solution containing 10 μm H2DCFDA and either thrombin or LMW-HA. Fluorescence was read at 535 nm using Wallac 1420 Multilabel plate reader. VSMC treated with thrombin or LMW-HA were incubated with 10 μm dihydroethidium (DHE, Invitrogen) at 37 °C for 30 min. DHE fluorescence was obtained at 590 nm in several visual fields using a Leica DMIRB fluorescent microscope.

In Vitro Hyaluronan Synthase Activity Assay

VSMC were treated with thrombin or vehicle for 6 h and hyaluronan synthase (HAS) activity assay was performed as described previously (31). Cells were washed, incubated in lysis buffer (10 mm KCl, 1.5 mm MgCl2, 10 mm Tris-HCl, pH 7.4) for 10 min, scraped, and homogenized using a Dounce homogenizer. Nuclei were removed by centrifuging at 1,000 × g for 4 min. Membrane fragments were separated by centrifugation at 16,000 × g for 25 min and resuspended in 100 μl of lysis buffer supplemented with protease inhibitors. HAS activity was determined in 100 μl of 25 mm HEPES (pH 7.1) containing 15 mm MgCl2, 5 mm dithiothreitol, 0.2 μg of aprotinin, 5 μg of leupeptin, 1 mm UDP-GlcNAc, 50 μm UDP-GlcA, 0.25 μCi of UDP-[14C]glucuronic acid, and 50 μg of cell membranes. The reaction mixture was incubated at 37 °C for 1 h and terminated by boiling. The reaction mixtures were divided in two and treated with or without Streptomyces hyaluronate lyase at 37 °C overnight and then with 200 mg/ml of Pronase for 5 h. Deproteinized samples were centrifuged in Amicon Ultracell-100 Centrifugal Filters (Millipore) to remove unincorporated [14C]glucuronic acid. Recovered samples were analyzed by liquid scintillation counting. HAS activity was calculated based on the incorporation rate of labeled glucuronic acid and as a fraction of HA removed by hyaluronate lyase treatment.

Histology and Immunostaining

The mouse hearts were perfused with PBS, embedded in OCT compound (Tissue-Tek), and snap-frozen in liquid nitrogen. Transverse serial sections were collected from the proximal aorta up to 560 μm of the cardiac tissue. Representative sections were stained with oil red O. Frozen sections were fixed in acetone and blocked with 0.3% H2O2 in methanol. Sections were immunostained with rat anti-mouse CD44 and CD11b antibodies (BD Pharmingen) or biotinylated HA-binding protein (Calbiochem) using the Vectastain Elite ABC Kit and Vector DAB Substrate Kit (Vector Laboratories). EPOSTM Anti-human Smooth Muscle Actin/HRP antibody (DakoCytomation) was used with Vector DAB Substrate Kit (Vector Laboratories). VSMC were grown on chamber glass slides, treated with thrombin and hyaluronidase from Streptomyces hyaluronlyticus (Calbiochem). Cells were fixed in methanol at −20 °C for 10 min and in acetone at −20 °C for 1 min. Staining for HA was carried out using biotinylated HA-binding protein (HABP) with Vectastain Elite ABC Kit and Vector DAB Substrate Kit (Vector Laboratories). The numeric immunohistochemistry scoring (1, weak; 2, moderate; and 3, strong staining intensity) was performed by two independent observers blinded to the sample identity.

Haptotactic Cell Migration Assay

Cell migration assays were performed using 8-μm pore size Transwell chambers (Corning). The bottom side of the filters was coated with 100 μg/ml of HMW-HA or BSA. The filters were washed and blocked with 2% BSA in PBS. VSMC treated with vehicle or thrombin for 8 h were trypsinized, centrifuged, and resuspended in DMEM. Cells were incubated with 2 units/ml of thrombin, rat anti-mouse CD44 monoclonal antibody (Millipore), or normal mouse IgG (Santa Cruz Biotechnology) at 37 °C for 30 min, and 2 × 104 cells were seeded on the top of Transwell filters. Cells were incubated at 37 °C for 16 h. Transwells were washed with PBS, cells from the top side of the filter were removed with a cotton swab, and cells on the bottom side of the filter were stained with hematoxylin (Vector Laboratories). The number of stained cells in 10 × 10-mm grid was scored for six random fields (×20 objective) per Transwell filter. The average number of cells that migrated per filter was calculated.

[3H]Thymidine Incorporation Assay

VSMC were plated at equal densities (2.5 × 104), quiesced, and either pretreated with thrombin for 8 h and then treated with LMW-HA for 24 h or treated with thrombin or LMW-HA for 24 h alone. [3H]Thymidine (1 μCi/ml) was added for the last 4 h of treatment. Cells were then washed, treated with cold 5% trichloroacetic acid at 4 °C for 30 min, and lysed in 1 m sodium hydroxide. [3H]Thymidine incorporation was determined by liquid scintillation counting.

Plasma Sample Collection and Hyaluronic Acid, Soluble CD44, and 8-Isoprostane ELISA

Blood samples were collected from deeply anesthetized mice through cardiac puncture and centrifuged at 1000 × g for 10 min for separation of plasma. Samples were stored at −80 °C until assayed. The concentration of HA in mouse plasma was measured using HA-ELISA (Echelon Biosciences) as described by the manufacturer. The Human CD44 ELISA kit (Cell Sciences) was used to measure soluble CD44 in mouse plasma and CD44 in protein lysates from mouse aortas. Plasma concentration of free 8-isoprostane was measured using the 8-isoprostane EIA Kit (Cayman Chemical) according to the manufacturer's protocol.

Statistical Analysis

Data were analyzed by one-way analysis of variance and post hoc analysis was performed using Newman-Keuls test. Student's t test was used to compare atherosclerosis, DHE fluorescence, 8-isoprostane levels, and immunohistochemistry scoring in mice treated with vehicle or GKT136901. Gene expression results in VSMC were analyzed by two-way analysis of variance followed by Bonferroni post-test. Differences were considered significant at p < 0.05.

RESULTS

Thrombin Induces Cd44 Expression in VSMC through NADPH Oxidase-dependent Activation of AP-1

We previously reported NADPH oxidase-dependent regulation of CD44 expression in wild-type VSMC treated with thrombin for 8 h (4). Consistent with these findings, a time-dependent activation of Cd44 mRNA expression was observed in response to thrombin treatment in wild-type VSMC, but not in p47phox−/− VSMC (Fig. 1A). To determine whether differences in Cd44 mRNA levels between wild-type and p47phox−/− VSMC were due to differences in gene transcription or mRNA stability, we first measured de novo transcription in nuclear run-on experiments. Thrombin treatment for 3 h resulted in a 2-fold increase in transcription of Cd44 RNA (p < 0.05) in wild-type VSMC but had no significant effect in p47phox−/− cells (Fig. 1B). The thrombin-induced increase in CD44 mRNA expression was effectively blocked by pretreatment with diphenyleneiodonium chloride, an inhibitor of NADPH oxidases and other flavin-containing enzymes. Further support for redox-dependent regulation of Cd44 mRNA expression was evident in wild-type VSMC treated with DMNQ, a redox cycling quinone known to induce ROS generation in VSMC (32).

FIGURE 1.
NADPH oxidase-dependent activation of AP-1 regulates thrombin-induced Cd44 gene expression. A, real time RT-PCR analysis of Cd44 expression in wild-type and p47phox−/− VSMC treated with thrombin. Data are expressed as fold-change in gene ...

Because the transcription factor AP-1 has been demonstrated to regulate CD44 expression during an inflammatory response in VSMC (33) and ROS have been implicated in the activation of AP-1 (34), we investigated activation of AP-1 in VSMC after treatment with thrombin. AP-1 DNA binding activity increased significantly (80%, p < 0.05) at 2 h and remained elevated for up to 4 h after thrombin treatment in wild-type but not in p47phox−/− cells (Fig. 1C). To determine whether NADPH oxidase-dependent increased AP-1 DNA binding activity is the mechanism for increased CD44 expression, wild-type and p47phox−/− VSMC were co-transfected with Cd44 promoter-luciferase reporter gene constructs containing either an AP-1 binding sequence (from 5′ −334 to 3′ +53 bp containing gctgcttagtca) or a mutant AP-1 binding sequence (−334 mAP-1 containing gctgcctaggca) (26). The transfected cells were then treated with thrombin. Luciferase activities were 6.7-fold higher in thrombin-treated wild-type VSMC compared with untreated cells (Fig. 1D). Wild-type cells transfected with the mutant AP-1 CD44 promoter-luciferase reporter gene construct showed almost complete inhibition of luciferase activity in response to thrombin treatment compared with wild-type cells transfected with the control AP-1 CD44 promoter-luciferase reporter gene construct. Importantly, transfection of p47phox−/− VSMC with either control or the mutant AP-1 CD44 promoter-luciferase reporter gene construct failed to show any significant increase in luciferase activity compared with their respective controls (Fig. 1D).

We next investigated whether thrombin enhances the expression of CD44 by altering the stability of Cd44 mRNA. The half-life of Cd44 mRNA in control and thrombin-treated wild-type VSMC was assessed by mRNA chase experiments using the transcription inhibitor actinomycin D. CdD44 mRNA stability was not altered by thrombin (Fig. 1E). Together, these results indicate that thrombin-induced CD44 expression in VSMC is regulated by AP-1 in NADPH oxidase-dependent manner.

Thrombin-induced HA Synthesis and Degradation in VSMC Are Regulated by NADPH Oxidase

A number of proatherogenic effects elicited by CD44 in vascular cells, including VSMC differentiation and activation (6), production of soluble inflammatory markers such as interleukin-12 (35), MCP-1 (36), iNOS (37), are largely mediated through the interaction of CD44 with HA (LMW-HA in particular). To determine whether activation of NADPH oxidase by thrombin has an effect on HA synthesis, we performed immunocytochemical analysis of wild-type and p47phox−/− VSMC treated with thrombin using HABP (Fig. 2A). Thrombin markedly increased HA synthesis in wild-type cells compared with p47phox−/− cells. Hyaluronidase treatment prior to immunostaining, to catabolize extracellular HA and thus demonstrate the specificity of HABP in recognizing HA, abrogated HA staining of both the cell types.

FIGURE 2.
NADPH oxidase regulates thrombin-induced increases in HAS2 and Hyal3 expression and HAS activity in VSMC. A, VSMC were treated with thrombin for 24 h. HA was detected using biotinylated HABP. Pericellular localization of HA was shown by treatment with ...

Hyaluronan synthase 2 (HAS2) is a major source of HA (38, 39). Quantitative RT-PCR analysis was used to determine whether the observed thrombin-induced increase in HA levels in wild-type VSMC resulted from increased synthesis. A time-dependent increase in Has2 expression was observed in wild-type VSMC treated with thrombin (Fig. 2B). A 3.6-fold increase (p < 0.01) in Has2 expression was observed in wild-type VSMC at 4 h after thrombin stimulation. Consistent with the putative role of NADPH oxidase in regulating HA levels, thrombin treatment had no significant effect on Has2 expression in p47phox−/− VSMC. Thrombin also had no significant effect on Has1 and Has3 expression in either cell type (data not shown). Thrombin-induced increase in Has2 mRNA levels was followed by a significant increase in the expression of HAS2 protein levels at 6 and 8 h in wild-type cells, but not in p47phox−/− cells (Fig. 2C). We then examined whether thrombin also regulates HAS activity in NADPH oxidase-dependent manner (Fig. 2D). Thrombin increased HAS activity by 40% in wild-type VSMC after 6 h treatment (p < 0.05), whereas it had no significant effect on the activity of this enzyme in p47phox−/− cells (Fig. 2D). Interestingly, thrombin treatment also caused a time-dependent increase in the expression of hyaluronidase 3 (Hyal3) in wild-type, but not in p47phox−/− VSMC (Fig. 2E). Hyal3 mRNA expression was 4.4-fold higher (p < 0.01) in wild-type VSMC than in p47phox−/− VSMC at 8 h after thrombin treatment. Thrombin had no significant effect on Hyal1 and Hyal2 expression in either cell type (data not shown). Taken together these data suggest that NADPH oxidase activation mediates thrombin-induced HA levels in VSMC by regulating both synthetic and degradation enzymes. Furthermore, ROS-regulated expression of Hyal3 may lead to enhanced degradation of HA and generation of biologically active LMW-HA.

Interaction of Thrombin with LMW-HA Induces ROS Generation in NADPH Oxidase-dependent Manner via the Activation of Rac1

A sustained and marked increase in thrombin concentration occurs after arterial injury (40) and active thrombin has been shown to be present in human atherosclerotic lesions (41). Accumulation of HA has been observed in the plaque/thrombus interface in humans (22). Because these events likely involve NADPH oxidase activation, we investigated whether thrombin and LMW-HA interaction increases oxidative stress in VSMC. First, we quantified ROS production by measuring DCF fluorescence. Thrombin caused a 50% increase (p < 0.05) in DCF fluorescence in wild-type VSMC, but no significant increase in p47phox−/− VSMC (Fig. 3A). LMW-HA treatment significantly increased DCF fluorescence in wild-type (p < 0.05) but not in p47phox−/− cells. Wild-type VSMC pretreated with thrombin for 8 h and then treated with LMW-HA had 90% higher fluorescence compared with control cells (p < 0.001) and 30% higher fluorescence than thrombin-treated cells (p < 0.05) (Fig. 3A). Thrombin pretreatment followed by LMW-HA treatment had no significant effect on DCF fluorescence in p47phox−/− cells. Similar to its effect in wild-type cells, thrombin increased DCF fluorescence by 50% (p < 0.05) in CD44−/− VSMC (Fig. 3A). However, LMW-HA alone or pretreatment with thrombin followed by LMW-HA treatment had no significant effect on DCF fluorescence in CD44−/− VSMC, indicating that interaction of thrombin-induced CD44 with LMW-HA induces ROS generation in VSMC.

FIGURE 3.
Thrombin enhances LMW-HA-induced VSMC NADPH oxidase activity by enhancing Rac1 activity. A, VSMC were treated with thrombin or LMW-HA alone or pretreated with thrombin for 8 h and then treated with LMW-HA. ROS generation was detected by measuring H2DCFDA ...

To confirm these results, we analyzed DHE fluorescence in wild-type, p47phox−/−, and CD44−/− VSMC treated with thrombin, LMW-HA, or both. A marked increase in DHE fluorescence was observed in wild-type and CD44−/− VSMC treated with thrombin (data not shown). DHE fluorescence was further enhanced in wild-type cells pretreated with thrombin for 8 h followed by treatment with LMW-HA, but not in CD44−/− VSMC. In contrast, none of these treatments significantly affected DHE fluorescence in p47phox−/− cells (data not shown).

Because both thrombin and HA are known to activate Rac1 GTPase (42, 43), a regulatory subunit of NADPH oxidase, we investigated the interaction of thrombin and LMW-HA on Rac1 activity by performing a PAK-1 PBD pulldown assay. Thrombin and LMW-HA increased Rac1 activity in wild-type cells by 80 and 70%, respectively (p < 0.05). Pretreatment with thrombin for 8 h prior to LMW-HA treatment increased Rac1 activity by 130% relative to untreated control (p < 0.001) and by 35% relative to LMW-HA treatment alone (p < 0.05) (Fig. 3B). Thrombin significantly increased Rac1 activity in CD44−/− VSMC (p < 0.05) (Fig. 3B), but LMW-HA or thrombin pretreatment followed by LMW-HA had no significant effect on Rac1 activity in CD44−/− VSMC. Thrombin, LMW-HA, or thrombin pretreatment followed by LMW-HA had no significant effect on the activation of Rac1 GTPase in p47phox−/− VSMC. Combined with our previous observations (4), these data suggest that NADPH oxidase is necessary for thrombin-induced CD44 expression and interaction of CD44 and HA, which in turn, activate NADPH oxidase.

LMW-HA Augments Thrombin-induced Proliferation of VSMC and CD44 Regulates Thrombin-induced Haptotactic Migration of VSMC toward HMW-HA

LMW-HA regulates VSMC proliferation in a CD44-dependent manner (6). To determine the role of ROS and confirm that of CD44 in LMW-HA-induced VSMC phenotype, we measured DNA synthesis in wild-type, p47phox−/−, and CD44−/− cells treated with LMW-HA. LMW-HA increased DNA synthesis in wild-type VSMC, although the increase was not statistically significant (Fig. 4A). Treatment with LMW-HA had no effect in CD44−/− cells. Thrombin significantly increased DNA synthesis in wild-type and CD44 knock-out VSMC (p < 0.01) but not in p47phox−/− cells, consistent with our prior findings (28) (Fig. 4A). Thrombin pretreatment for 8 h prior to LMW-HA treatment increased [3H]thymidine uptake in wild-type VSMC by 3.5-fold compared with untreated cells (p < 0.001) and by 2.2-fold compared with LMW-HA treatment alone (p < 0.01). LMW-HA or thrombin pretreatment followed by LMW-HA had no significant effect on DNA synthesis in p47phox−/− or CD44−/− cells. Together, these results indicate that interaction of LMW-HA with NADPH oxidase-dependent increased CD44 expression plays an important role in VSMC proliferation.

FIGURE 4.
LMW-HA enhances thrombin-induced VSMC proliferation and functional inhibition of CD44 attenuates thrombin-induced haptotactic migration of VSMC toward HMW-HA. A, growth-arrested VSMC treated with thrombin or LMW-HA or pretreated with thrombin for 8 h ...

Because CD44 isoforms were known to enhance migration of melanoma cells on HA-coated surfaces (44, 45), we investigated whether CD44 regulates thrombin-induced migration of VSMC. In a haptotactic cell migration assay, a greater number of wild-type cells migrated toward HA as compared with bovine serum albumin. Treatment with thrombin significantly increased VSMC migration toward HA compared with untreated control (p < 0.05) (Fig. 4B). Thrombin pretreatment for 8 h followed by thrombin treatment further enhanced VSMC migration toward HA compared with thrombin treatment alone (p < 0.05). The migration of VSMC toward HA in response to thrombin alone and thrombin pretreatment + thrombin was significantly inhibited (p < 0.05) by anti-CD44 mAb, whereas isotype-matched mouse IgG had no inhibitory effect on the migration induced by thrombin pretreatment + thrombin treatment. Together with the published data (4), these CD44 functional inhibition studies indicate that thrombin-induced NADPH oxidase-dependent increased CD44 expression plays an important role in migration toward HA and LMW-HA-stimulated proliferation of VSMC.

NADPH Oxidase Regulates Expression of CD44 in the Aortas and HA in the Atherosclerotic Lesions

We previously reported lower levels of immunoreactive CD44 in atherosclerotic lesions in the aortas of apoE−/−/p47phox−/− mice compared with apoE−/− mice, correlating with the decreased lesion size in apoE−/−/p47phox−/− animals (4). Here, we compared the systemic expression of CD44 in protein lysates from aortas of apoE−/− and apoE−/−/p47phox−/− mice fed a Western diet. The amount of CD44 in lysates from apoE−/− aortas was 2.6-fold higher than that from apoE−/−/p47phox−/− animals (p < 0.001) (Fig. 5A) as measured by ELISA.

FIGURE 5.
CD44 expression is enhanced in aortas of apoE−/− mice, whereas HA expression was up-regulated in atherosclerotic lesions of apoE−/− mice as compared with apoE−/−/p47phox−/− mice. A, CD44 ...

Because expression of CD44 and its interaction with HA are important determinants of the extent of atherosclerotic lesions in mice (6), we performed immunohistochemical analysis of HA expression in aortic sections of apoE−/− and apoE−/−/p47phox−/− mice fed a Western diet. HA expression was significantly increased in apoE−/− aortic sections compared with those from apoE−/−/p47phox−/− mice (p < 0.05) as detected by immunostaining using HA-binding protein, followed by histological scoring (Fig. 5, B and C). Intense HA expression was observed in the medial layer as confirmed by smooth muscle α-actin staining and in macrophage-enriched, oil red O positive areas of plaques (Fig. 5B).

These in vivo findings suggest that mechanisms similar to those observed in cultured VSMC for NADPH oxidase regulation of CD44 and HA expressions are important in vivo. Increased systemic expression of CD44 in apoE−/− aortas also indicates the role of NADPH oxidase in the induction of a pro-inflammatory milieu in mice.

Plasma Soluble CD44 and HA Levels Are Down-regulated in ApoE−/− Mice Deficient in p47phox Subunit of NADPH Oxidase

Shedding and release of soluble CD44 into the systemic circulation is induced by various cytokines (46) and HA degradation and turnover are regulated by ROS, processes characteristic of an inflammatory response (18, 47). Furthermore, increased plasma HA levels have been associated with diabetic angiopathy and the susceptibility of diabetic patients to atherosclerosis (48, 49). Because the activation of NADPH oxidases contributes to inflammation (50, 51), we investigated soluble CD44 and HA levels in the plasma of apoE−/− and apoE−/−/p47phox−/− mice on a Western diet. Soluble CD44 levels increased significantly in apoE−/− mice as compared with apoE−/−/p47phox−/− and wild-type mice (p < 0.05) (Fig. 6A). Similarly, plasma HA levels in apoE−/−/p47phox−/− mice were significantly lower than those in apoE−/− mice (p < 0.01) (Fig. 6B). There was no significant difference in either plasma-soluble CD44 or HA levels between wild-type and apoE−/−/p47phox−/− mice. These data support our observation of increased expression of CD44 and HA in the aortic wall of apoE−/− mice. Furthermore, they suggest that increased NADPH oxidase-dependent degradation of HA and shedding and release of soluble CD44 antigen into systemic circulation enhance the inflammatory process and promote atherosclerosis in proatherogenic milieu.

FIGURE 6.
HA and soluble CD44 concentrations are increased in the plasma of apoE−/− as compared with wild-type and apoE−/−/p47phox−/− mice. A, soluble CD44 concentration in the plasma of wild-type, apoE−/− ...

CD44 and HA-dependent Gene Expression is Regulated in ApoE−/− Mice in a NADPH Oxidase-dependent Manner

Interaction of CD44 with LMW-HA results in the induction of chemokine gene expression in macrophages (36) and CD44 regulates vascular gene expression in atherosclerosis-prone regions of the vasculature (52). Soluble HA was shown to induce the expression of Il1β, Tnfα, and Igf1 in bone-marrow derived macrophages (53) and Ccl2, Ccl4, and Ccl5 in alveolar macrophages (36). We performed gene expression analysis of aortas from mice fed a Western diet to determine whether NADPH oxidase-dependent, increased expression of CD44 and HA will result in increased expression of the aforementioned genes in apoE−/− mice as compared with apoE−/−/p47phox−/− mice. Real time RT-PCR analysis showed significantly higher levels of Ccl2, Ccl5, Tnfα, and Igf1 expression in aortas of apoE−/− mice compared with the double knock-out mice (p < 0.05) (Table 1). Differences in the expression of Ccl4 and Il1β trended to higher levels but were not significant. These results suggest that NADPH oxidase-dependent expression of CD44 and HA in the vascular wall and ROS-dependent HA degradation and release of LMW-HA leads to increased interaction of CD44 and LMW-HA and induction of pro-inflammatory cytokine expression in the vasculature and that this promotes atherogenesis.

TABLE 1
Analysis of gene expression in aortas of apoE−/−versus apoE−/−/p47phox−/− mice

Pharmacologic Inhibition of Nox1/Nox4-based NADPH Oxidase Attenuates Atherosclerosis, ROS Generation, Plasma 8-Isoprostane Levels, and CD44 and HA Expression in Atherosclerotic Lesions of ApoE−/− Mice

To confirm the role of NADPH oxidase in the regulation of CD44 and HA expression under pathophysiologic conditions, we tested the effect of GKT136901 (Fig. 7A), a dual Nox1/Nox4 inhibitor, on atherosclerosis development in apoE−/− mice and the presence of CD44 and HA in atherosclerotic lesions. Nox4 regulates VSMC migration (3) and its expression is significantly enhanced in apoE−/− mice compared with wild-type mice (54). GKT136901 has a Ki in the range of 150–250 nm for human Nox1 and Nox4 (Emax of 90–100% at 33 μm) in a cell-free system and is bioavailable following oral administration.4

FIGURE 7.
Treatment with GKT136901, a pharmacologic inhibitor of Nox1/Nox4-based NADPH oxidases, decreases atherosclerosis, ROS generation, plasma 8-isoprostane levels, and CD44 and HA expression in atherosclerotic lesions in apoE−/− mice. A, chemical ...

GKT136901 treatment significantly decreased the aortic atherosclerotic lesion area compared with vehicle treatment (p < 0.05) (Fig. 7B). There was no significant effect of GKT136901 on body weight, plasma total cholesterol, or triglyceride levels (Table 2). GKT136901 did significantly inhibit aortic ROS production as measured by the decrease in DHE fluorescence of fresh-frozen cross-sections (p < 0.05 versus vehicle) (Fig. 7C). To quantify systemic oxidative stress, plasma 8-isoprostane levels were determined using the Enzyme Immunoassay kit. A modest but significant decrease (p < 0.05) in plasma 8-isoprostane levels was observed in apoE−/− mice treated with GKT136901 compared with mice treated with the vehicle (Fig. 7D). Immunostaining of aortic cross-sections showed a significant decrease in CD44 and HA expression in atherosclerotic lesions of apoE−/− mice treated with GKT136901 compared with those from mice treated with the vehicle (Fig. 7, E and F). Furthermore, expression of monocyte/macrophage marker, CD11b, was significantly decreased in atherosclerotic lesions in mice treated with GKT136901 compared with the vehicle treatment (Fig. 7, E and F). These results support our in vitro data that NADPH oxidases regulate CD44 and HA expression and together with other published reports (4) indicate that CD44- and HA-dependent inflammatory cell recruitment and VSMC activation promotes atherosclerosis.

TABLE 2
Body weight, plasma cholesterol, and triglycerides levels in apoE−/− mice fed a Western diet and treated with vehicle or GKT136901 (mean ± S.E., n = 15)

Thrombin Regulates HASMC CD44 and HA Expression in Nox1/Nox4-based NADPH Oxidase-dependent Manner

To determine whether CD44 and HAS2 are regulated in a similar manner in human vascular cells, we investigated thrombin-induced CD44 and HAS2 expression in HASMC. Western blot analysis revealed that thrombin regulates these proteins in a time-dependent manner, with peak CD44 expression at 4 h and HAS2 at 8 h (Fig. 8A). As an approach to determine the importance of NADPH oxidase in CD44 and HAS2 expression in HASMC, we treated cells with thrombin in the presence and absence of GKT136901. Pretreatment of HASMC with 30 μm GKT136901 for 1 h prior to thrombin treatment significantly inhibited intracellular ROS generation as measured by DCF fluorescence (p < 0.01) (Fig. 8B). GKT136901 also significantly inhibited thrombin-induced Cd44 mRNA levels at 2 and 4 h (p < 0.001 and p < 0.05, respectively) and Has2 mRNA levels at 2 h (p < 0.01) (Fig. 8, C and D) without significantly affecting Nox1 or Nox4 expression (data not shown). Consistent with this, GKT136901 abrogated any thrombin-induced increase in CD44 and HAS2 proteins levels (Fig. 8, E and F). Together with mouse cell culture and atherosclerosis model results, these data underline the relevance of ROS-sensitive regulation of CD44, HAS2, and HA expression in human atherosclerosis development.

FIGURE 8.
GKT136901 inhibits thrombin-induced CD44 and HAS2 expression in HASMC. A, growth-arrested HASMC were treated with thrombin for the indicated times. Expression of CD44 and HAS2 was determined by Western blot analysis. B, HASMC were treated with thrombin ...

DISCUSSION

The experiments reported here demonstrate that: 1) NADPH oxidase regulates thrombin induced CD44 expression via activation of AP-1; 2) increased synthesis and degradation of HA in thrombin-treated VSMC is regulated in NADPH oxidase-dependent manner; 3) LMW-HA enhances oxidative stress by activating Rac1 and subsequent induction of NADPH oxidase activity; 4) interaction of LMW-HA with NADPH oxidase-dependent increased CD44 expression in thrombin-treated VSMC plays a vital role in cell proliferation and migration; 5) CD44- and HA-dependent gene expression is significantly up-regulated in the aortas of apoE−/− mice compared with apoE−/−/p47phox−/− mice; and 6) GKT136901, a pharmacological inhibitor of Nox1/Nox4-based NADPH oxidases not only inhibits oxidative stress, CD44 and HA expression, and atherosclerosis in apoE−/− mice, but also attenuates thrombin-induced ROS generation, CD44 and HA expression in HASMC. Together, these studies indicate that CD44 and HA constitute a Nox homologue-independent NADPH oxidase-regulated redox-sensitive signaling pathway active in the pathogenesis of atherosclerosis.

We and others have reported that CD44 expression is enhanced in response to arterial injury, inflammation, and atherosclerosis (4, 6, 33), interrelated pathologic processes that are regulated in a redox-sensitive manner (55). Our in vitro data that thrombin-stimulated CD44 expression is regulated by transcription factor AP-1 is consistent with the redox-sensitive regulation of this adhesion molecule and is in agreement with other reports (26, 33).

HA is synthesized in VSMC by three HA synthases (56), however, HAS2 is almost certainly the major HA synthesizing enzyme in VSMC based on two lines of evidence. First, when Has2 is down-regulated using siRNA, VSMC proliferation is inhibited (23). Second, VSMC-specific overexpression of HAS2 enhances atherosclerosis in apoE−/− mice (20). Our data indicate that increased HAS2 expression and activity in response to thrombin treatment is dependent on NADPH oxidase activation. Furthermore, our data indicating that that NADPH oxidase regulates Hyal3 expression in VSMC treated with thrombin is significant because increased HA during pathological conditions is the sum of its synthesis and catabolism. This is also an interesting observation because Hyal3−/− mice do not exhibit any HA accumulation (57) and cellular overexpression of Hyal3 does not impart intrinsic hyaluronidase activity (58). In contrast, up-regulation of Hyal3 was reported in chondrocytes treated with cytokines (59). Although ROS can cleave HA in laboratory tests (17) and HA levels have been positively correlated with other oxidative stress makers in diabetic patients (47), evidence for the direct action of ROS on HA degradation in studies using cell culture or cell-free extracts is absent.

The increase in thrombin-induced NADPH oxidase activity by LMW-HA may be due to either enhanced Rac1 activity (Fig. 3B) or enhanced CD44 expression caused by thrombin pretreatment, or both. HA has been reported to induce ROS production in a CD44-dependent manner (43, 60) and NADPH oxidase mediates the increase in ROS production as down-regulation of p47phox, p67phox, or Rac1 decreased ROS levels (43). Arterial injury and atherosclerotic lesions are characterized by enhanced thrombin expression and activity (40, 41) and increased ROS production in the arteries of apoE−/− versus apoE−/−/p47phox−/− mice (29) may result from the interaction of increased thrombin and HA levels. NADPH oxidase activation increases HA synthesis and LMW-HA enhances NADPH oxidase activity suggesting a positive feedback loop between HA and NADPH oxidase activation.

Increased VSMC migration and proliferation are important events in the development of atherosclerosis and restenosis. Wild-type VSMC proliferate more rapidly than p47phox−/− VSMC in the presence of thrombin and LMW-HA, indicating that NADPH oxidase activation and subsequent synthesis of CD44 are major contributors of VSMC mitogenesis likely in vivo under pathophysiological conditions. The importance of NADPH oxidase-dependent CD44 expression in atherogenesis is supported by our finding that thrombin-induced haptotactic migration of VSMC is significantly decreased in the presence of monoclonal anti-CD44 antibody.

The increase in CD44 expression observed in the current investigation in the aortas of apoE−/− mice (compared with those in apoE−/−/p47phox−/− mice) together with the observation of Cuff et al. (6) that CD44−/−/apoE−/− mice develop significantly decreased atherosclerosis (again compared with apoE−/− littermates) indicates that NADPH oxidases and CD44 play a critical role in atherogenesis. The increase in plasma sCD44 levels in apoE−/− mice compared with wild-type and apoE−/−/p47phox−/− mice further indicates that activation of NADPH oxidase in proatherogenic milieu releases sCD44 by proteolytic cleavage of membrane-anchored CD44. This may well be from the stimulation of matrix metalloproteinases (61, 62). Our in vivo data showing increased HA expression in medial VSMC of atherosclerotic lesions in apoE−/− mice compared with apoE−/−/p47phox−/− mice supports our cell culture data of decreased HA levels in p47phox−/− VSMC compared with wild-type in response to thrombin treatment. These findings are consistent with the observation of Chai et al. (20) that overexpression of HA in aortic VSMC of apoE−/− mice increases atherosclerosis. Interestingly, apoE−/− mice had higher plasma HA levels than wild-type and apoE−/−/p47phox−/− mice consistent with increased HA degradation under proatherogenic conditions.

In addition to their role in VSMC proliferation and migration, CD44 and HA participate in many processes that promote atherogenesis. For example, CD44 contributes to the initial rolling interaction between lymphocytes and endothelium and once within the subendothelial space, CD44 mediates interactions between leukocytes, VSMC, and parenchymal cells (19). In this context it is noteworthy that pharmacologic inhibition of Nox1/Nox4-based NADPH oxidase in apoE−/− mice not only attenuated ROS generation in the aortic wall and plasma 8-isoprostane levels but also decreased atherosclerotic burden, CD44 and HA levels in the aortic wall and macrophage recruitment into these lesions (Fig. 7). To our knowledge, this is the first study to show that a specific inhibitor of Nox1/Nox4 activity significantly decrease atherosclerosis in apoE−/− mice. This inhibitor may have therapeutic potential as it inhibited CD44 and HA expression and oxidative stress in HASMC. Increased HA levels in medial VSMC were correlated with increased mechanical stiffness and strength of the aortas, which is linked to endothelial dysfunction and atherogenesis (20, 63). Because HA interacts with lipoproteins through hydrophobic interactions (64), increased HA might promote atherogenesis by retaining lipoproteins in the arterial wall.

Finally, our analysis of known HA-regulated genes (36, 53) in the aortas of apoE−/− and apoE−/−/p47phox−/− mice demonstrated a NADPH oxidase-dependent regulation of Ccl2 (Mcp1), Ccl5 (RANTES), Tnfα, and Igf1. MCP-1 plays an important role in the recruitment of monocytes/macrophages to vascular lesions. Localized overexpression of MCP-1 in the vessel wall, in the backdrop of hypercholesterolemia, induces early atherosclerotic lesions in rabbits (65) and increased expression of serum MCP-1 was observed in hypertensive patients with diffuse atherosclerosis as well (66). In concurrence with our results, Bae et al. (67) have recently reported that RANTES is regulated in a NADPH oxidase-dependent manner. Furthermore, a transient increase in RANTES levels was reported in patients experiencing unstable angina pectoris (68). TNF-α plays a key role in the inflammatory cascade associated with atherosclerosis (69) and several studies support the association of increased TNF-α levels with increased risk of myocardial infarction (70, 71). The role of IGF-1 in atherogenesis is controversial. Several studies suggest that IGF-1 accelerates atherogenesis (72, 73), whereas another study has reported an association of low serum IGF-1 levels with increased risk for ischemic heart disease (74). Our data indicating pharmacologic inhibition of Nox1/Nox4-based NADPH oxidase markedly decreases CD44 and HA expression in the vascular wall validates our hypothesis that NADPH oxidase activation promotes atherosclerosis via CD44- and HA-dependent processes.

In summary, our data provide insight into the molecular mechanisms by which NADPH oxidase activation promotes atherosclerotic lesion formation. NADPH oxidases mediate agonist-induced HA synthesis by regulating both HA synthetic and degradation enzymes and a positive feedback loop between HA and NADPH oxidase increases oxidative stress and enhances atherosclerosis. Interaction between increased CD44 and HA levels resulting from NADPH oxidase activation in hyperlipidemic background induces chemokine, cytokine, and growth factor production, which promote atherosclerosis. Specific inhibitors of NADPH oxidase function may provide an effective therapy for treating atherosclerosis not just by decreasing oxidative burden but also by attenuating the molecular pathways that promote atherosclerosis.

*This work was supported, in whole or in part, by National Institutes of Health Grants HL-57352 and AG 024282.

4C. Szyndralewiez and P. Page, unpublished data.

3The abbreviations used are:

ROS
reactive oxygen species
VSMC
vascular smooth muscle cells
HA
hyaluronic acid
Has2
hyaluronan synthase 2
Hyal3
hyaluronidase 3
LMW-HA
low-molecular weight HA
HMW-HA
high-molecular weight HA
DMNQ
2,3-dimethoxy-1,4-naphthoquinone
GKT136901
2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-yl-methyl)-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione)
HABP
HA-binding protein
HASMC
human aortic smooth muscle cell
PBD
p21 binding domain
DHE
dihydroethidium
IGF-1
insulin-like growth factor 1
PAK-1
p21-activated protein kinase 1
MCP-1
monocyte chemoattractant protein-1
DCFDA
2′,7′-dichlorofluorescin diacetate.

REFERENCES

1. Bedard K., Krause K. H. (2007) Physiol. Rev. 87, 245–313 [PubMed]
2. Hilenski L. L., Clempus R. E., Quinn M. T., Lambeth J. D., Griendling K. K. (2004) Arterioscler. Thromb. Vasc. Biol. 24, 677–683 [PubMed]
3. Lyle A. N., Deshpande N. N., Taniyama Y., Seidel-Rogol B., Pounkova L., Du P., Papaharalambus C., Lassègue B., Griendling K. K. (2009) Circ. Res. 105, 249–259 [PMC free article] [PubMed]
4. Vendrov A. E., Madamanchi N. R., Hakim Z. S., Rojas M., Runge M. S. (2006) Circ. Res. 98, 1254–1263 [PubMed]
5. Ponta H., Sherman L., Herrlich P. A. (2003) Nat. Rev. Mol. Cell Biol. 4, 33–45 [PubMed]
6. Cuff C. A., Kothapalli D., Azonobi I., Chun S., Zhang Y., Belkin R., Yeh C., Secreto A., Assoian R. K., Rader D. J., Puré E. (2001) J. Clin. Invest. 108, 1031–1040 [PMC free article] [PubMed]
7. Krettek A., Sukhova G. K., Schönbeck U., Libby P. (2004) Am. J. Pathol. 165, 1571–1581 [PubMed]
8. Hägg D., Sjöberg S., Hultén L. M., Fagerberg B., Wiklund O., Rosengren A., Carlsson L. M., Borén J., Svensson P. A., Krettek A. (2007) Atherosclerosis 190, 291–297 [PubMed]
9. Jain M., He Q., Lee W. S., Kashiki S., Foster L. C., Tsai J. C., Lee M. E., Haber E. (1996) J. Clin. Invest. 97, 596–603 [PMC free article] [PubMed]
10. Okamoto I., Tsuiki H., Kenyon L. C., Godwin A. K., Emlet D. R., Holgado-Madruga M., Lanham I. S., Joynes C. J., Vo K. T., Guha A., Matsumoto M., Ushio Y., Saya H., Wong A. J. (2002) Am. J. Pathol. 160, 441–447 [PubMed]
11. Mayer S., zur Hausen A., Watermann D. O., Stamm S., Jäger M., Gitsch G., Stickeler E. (2008) J. Cancer Res. Clin. Oncol. 134, 1229–1235 [PubMed]
12. Sjöberg S., Fogelstrand L., Hulthe J., Fagerberg B., Krettek A. (2005) Metabolism 54, 139–141 [PubMed]
13. Stern R., Asari A. A., Sugahara K. N. (2006) Eur. J. Cell Biol. 85, 699–715 [PubMed]
14. Toole B. P., Wight T. N., Tammi M. I. (2002) J. Biol. Chem. 277, 4593–4596 [PubMed]
15. Philipson L. H., Westley J., Schwartz N. B. (1985) Biochemistry 24, 7899–7906 [PubMed]
16. Evanko S. P., Johnson P. Y., Braun K. R., Underhill C. B., Dudhia J., Wight T. N. (2001) Arch. Biochem. Biophys. 394, 29–38 [PubMed]
17. Harada H., Takahashi M. (2007) J. Biol. Chem. 282, 5597–5607 [PubMed]
18. McNeil J. D., Wiebkin O. W., Betts W. H., Cleland L. G. (1985) Ann. Rheum. Dis. 44, 780–789 [PMC free article] [PubMed]
19. Puré E., Cuff C. A. (2001) Trends Mol. Med. 7, 213–221 [PubMed]
20. Chai S., Chai Q., Danielsen C. C., Hjorth P., Nyengaard J. R., Ledet T., Yamaguchi Y., Rasmussen L. M., Wogensen L. (2005) Circ. Res. 96, 583–591 [PubMed]
21. Riessen R., Wight T. N., Pastore C., Henley C., Isner J. M. (1996) Circulation 93, 1141–1147 [PubMed]
22. Kolodgie F. D., Burke A. P., Farb A., Weber D. K., Kutys R., Wight T. N., Virmani R. (2002) Arterioscler. Thromb. Vasc. Biol. 22, 1642–1648 [PubMed]
23. van den Boom M., Sarbia M., von Wnuck Lipinski K., Mann P., Meyer-Kirchrath J., Rauch B. H., Grabitz K., Levkau B., Schrör K., Fischer J. W. (2006) Circ. Res. 98, 36–44 [PubMed]
24. Miyazaki T., Yomota C., Okada S. (2001) Polymer Degradation and Stability 74, 77–85
25. Page P., Orchard M., Fioraso-Cartier L., Mottironi B. (2008) Pyrazolo Pyridine Derivatives as NADPH Oxidase Inhibitors, WO 2008=113856 A1, GenKyoTex
26. Mishra J. P., Mishra S., Gee K., Kumar A. (2005) J. Biol. Chem. 280, 26825–26837 [PubMed]
27. Moon S. K., Thompson L. J., Madamanchi N., Ballinger S., Papaconstantinou J., Horaist C., Runge M. S., Patterson C. (2001) Am. J. Physiol. Heart Circ. Physiol. 280, H2779–H2788 [PubMed]
28. Madamanchi N. R., Li S., Patterson C., Runge M. S. (2001) J. Biol. Chem. 276, 18915–18924 [PubMed]
29. Barry-Lane P. A., Patterson C., van der Merwe M., Hu Z., Holland S. M., Yeh E. T., Runge M. S. (2001) J. Clin. Invest. 108, 1513–1522 [PMC free article] [PubMed]
30. Pfaffl M. W., Horgan G. W., Dempfle L. (2002) Nucleic Acids Res. 30, e36. [PMC free article] [PubMed]
31. Stuhlmeier K. M. (2005) J. Immunol. 174, 7376–7382 [PubMed]
32. Tchivilev I., Madamanchi N. R., Vendrov A. E., Niu X. L., Runge M. S. (2008) J. Biol. Chem. 283, 22193–22205 [PMC free article] [PubMed]
33. Foster L. C., Wiesel P., Huggins G. S., Pañares R., Chin M. T., Pellacani A., Perrella M. A. (2000) FASEB J. 14, 368–378 [PubMed]
34. Rao G. N., Katki K. A., Madamanchi N. R., Wu Y., Birrer M. J. (1999) J. Biol. Chem. 274, 6003–6010 [PubMed]
35. Hodge-Dufour J., Noble P. W., Horton M. R., Bao C., Wysoka M., Burdick M. D., Strieter R. M., Trinchieri G., Puré E. (1997) J. Immunol. 159, 2492–2500 [PubMed]
36. McKee C. M., Penno M. B., Cowman M., Burdick M. D., Strieter R. M., Bao C., Noble P. W. (1996) J. Clin. Invest. 98, 2403–2413 [PMC free article] [PubMed]
37. McKee C. M., Lowenstein C. J., Horton M. R., Wu J., Bao C., Chin B. Y., Choi A. M., Noble P. W. (1997) J. Biol. Chem. 272, 8013–8018 [PubMed]
38. Camenisch T. D., Spicer A. P., Brehm-Gibson T., Biesterfeldt J., Augustine M. L., Calabro A., Jr., Kubalak S., Klewer S. E., McDonald J. A. (2000) J. Clin. Invest. 106, 349–360 [PMC free article] [PubMed]
39. Noble P. W. (2002) Matrix Biol. 21, 25–29 [PubMed]
40. Walters T. K., Gorog D. A., Wood R. F. (1994) J. Vasc. Res. 31, 173–177 [PubMed]
41. Westmuckett A. D., Lupu C., Goulding D. A., Das S., Kakkar V. V., Lupu F. (2000) Thromb. Haemost. 84, 904–911 [PubMed]
42. Diebold I., Djordjevic T., Petry A., Hatzelmann A., Tenor H., Hess J., Görlach A. (2009) Circ. Res. 104, 1169–1177 [PubMed]
43. Kim Y., Lee Y. S., Choe J., Lee H., Kim Y. M., Jeoung D. (2008) J. Biol. Chem. 283, 22513–22528 [PubMed]
44. Thomas L., Byers H. R., Vink J., Stamenkovic I. (1992) J. Cell Biol. 118, 971–977 [PMC free article] [PubMed]
45. Yoshinari C., Mizusawa N., Byers H. R., Akasaka T. (1999) Melanoma Res. 9, 223–231 [PubMed]
46. Cichy J., Kulig P., Puré E. (2005) Biochim. Biophys. Acta 1745, 59–64 [PubMed]
47. Gao F., Koenitzer J. R., Tobolewski J. M., Jiang D., Liang J., Noble P. W., Oury T. D. (2008) J. Biol. Chem. 283, 6058–6066 [PMC free article] [PubMed]
48. Mine S., Okada Y., Kawahara C., Tabata T., Tanaka Y. (2006) Endocr. J. 53, 761–766 [PubMed]
49. Nieuwdorp M., Holleman F., de Groot E., Vink H., Gort J., Kontush A., Chapman M. J., Hutten B. A., Brouwer C. B., Hoekstra J. B., Kastelein J. J., Stroes E. S. (2007) Diabetologia 50, 1288–1293 [PMC free article] [PubMed]
50. Wei Y., Whaley-Connell A. T., Chen K., Habibi J., Uptergrove G. M., Clark S. E., Stump C. S., Ferrario C. M., Sowers J. R. (2007) Hypertension 50, 384–391 [PubMed]
51. Basuroy S., Bhattacharya S., Leffler C. W., Parfenova H. (2009) Am. J. Physiol. Cell Physiol. 296, C422–C432 [PubMed]
52. Zhao L., Hall J. A., Levenkova N., Lee E., Middleton M. K., Zukas A. M., Rader D. J., Rux J. J., Puré E. (2007) Arterioscler. Thromb. Vasc. Biol. 27, 886–892 [PubMed]
53. Noble P. W., Lake F. R., Henson P. M., Riches D. W. (1993) J. Clin. Invest. 91, 2368–2377 [PMC free article] [PubMed]
54. Xu X., Gao X., Potter B. J., Cao J. M., Zhang C. (2007) Arterioscler. Thromb. Vasc. Biol. 27, 871–877 [PubMed]
55. Ali Z. A., Bursill C. A., Douglas G., McNeill E., Papaspyridonos M., Tatham A. L., Bendall J. K., Akhtar A. M., Alp N. J., Greaves D. R., Channon K. M. (2008) Circulation. 118, Suppl. 14, S71–S77 [PubMed]
56. Fischer J. W., Schrör K. (2007) Thromb. Haemost. 98, 287–295 [PubMed]
57. Atmuri V., Martin D. C., Hemming R., Gutsol A., Byers S., Sahebjam S., Thliveris J. A., Mort J. S., Carmona E., Anderson J. E., Dakshinamurti S., Triggs-Raine B. (2008) Matrix Biol. 27, 653–660 [PubMed]
58. Hemming R., Martin D. C., Slominski E., Nagy J. I., Halayko A. J., Pind S., Triggs-Raine B. (2008) Glycobiology 18, 280–289 [PubMed]
59. Flannery C. R., Little C. B., Hughes C. E., Caterson B. (1998) Biochem. Biophys. Res. Commun. 251, 824–829 [PubMed]
60. Basoni C., Reuzeau E., Croft D., Génot E., Kramer I. M. (2006) Biochem. Biophys. Res. Commun. 343, 609–616 [PubMed]
61. Inoue N., Takeshita S., Gao D., Ishida T., Kawashima S., Akita H., Tawa R., Sakurai H., Yokoyama M. (2001) Atherosclerosis 155, 45–52 [PubMed]
62. Deem T. L., Cook-Mills J. M. (2004) Blood 104, 2385–2393 [PMC free article] [PubMed]
63. Peng X., Haldar S., Deshpande S., Irani K., Kass D. A. (2003) Hypertension 41, 378–381 [PubMed]
64. Srinivasan S. R., Yost K., Radhakrishnamurthy B., Dalferes E. R., Jr., Berenson G. S. (1980) Atherosclerosis 36, 25–37 [PubMed]
65. Namiki M., Kawashima S., Yamashita T., Ozaki M., Hirase T., Ishida T., Inoue N., Hirata K., Matsukawa A., Morishita R., Kaneda Y., Yokoyama M. (2002) Arterioscler. Thromb. Vasc. Biol. 22, 115–120 [PubMed]
66. Tucci M., Quatraro C., Frassanito M. A., Silvestris F. (2006) J. Hypertens. 24, 1307–1318 [PubMed]
67. Bae Y. S., Lee J. H., Choi S. H., Kim S., Almazan F., Witztum J. L., Miller Y. I. (2009) Circ. Res. 104, 210–218 [PMC free article] [PubMed]
68. Kraaijeveld A. O., de Jager S. C., de Jager W. J., Prakken B. J., McColl S. R., Haspels I., Putter H., van Berkel T. J., Nagelkerken L., Jukema J. W., Biessen E. A. (2007) Circulation 116, 1931–1941 [PubMed]
69. Hansson G. K. (2001) Arterioscler. Thromb. Vasc. Biol. 21, 1876–1890 [PubMed]
70. Cesari M., Penninx B. W., Newman A. B., Kritchevsky S. B., Nicklas B. J., Sutton-Tyrrell K., Rubin S. M., Ding J., Simonsick E. M., Harris T. B., Pahor M. (2003) Circulation 108, 2317–2322 [PubMed]
71. Bennet A. M., van Maarle M. C., Hallqvist J., Morgenstern R., Frostegård J., Wiman B., Prince J. A., de Faire U. (2006) Atherosclerosis 187, 408–414 [PubMed]
72. Kawachi S., Takeda N., Sasaki A., Kokubo Y., Takami K., Sarui H., Hayashi M., Yamakita N., Yasuda K. (2005) Arterioscler. Thromb. Vasc. Biol. 25, 617–621 [PubMed]
73. Colao A., Spiezia S., Di Somma C., Pivonello R., Marzullo P., Rota F., Musella T., Auriemma R. S., De Martino M. C., Lombardi G. (2005) J. Endocrinol. Invest. 28, 440–448 [PubMed]
74. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jørgensen T. (2002) Circulation 106, 939–944 [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology